Figure 1From: Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation studyResponse rate during DSG treatment. Response rate (CR in black, PR in dark grey, SD in bright grey, TF in white) at cycles (CYC) 4, 6 and 9 (ITT population). *In both cycles 4 and 6, three patients were not assessable.Back to article page